4/A: Apimeds Pharmaceuticals Insider Inscobee Inc. Converts $299K in Notes to Equity, Corrects Ownership Filing
Amendment to Insider Ownership Report
Inscobee Inc., a 10% owner and director of Apimeds Pharmaceuticals US, Inc., has converted $299,340 in convertible promissory notes into 115,131 shares of common stock, while also amending a previous filing to clarify direct beneficial ownership.
Summary
- Inscobee Inc., a 10% owner and director of Apimeds Pharmaceuticals US, Inc. (APUS), converted two convertible promissory notes into common stock on May 12, 2025.
- The first note, issued March 21, 2022, with a principal of $160,000 and $24,833 in accrued interest (totaling $184,833), converted into 71,090 shares of common stock at a conversion price of $2.60 per share.
- The second note, issued June 3, 2022, with a principal of $100,000 and $14,507 in accrued interest (totaling $114,507), converted into 44,041 shares of common stock at a conversion price of $2.60 per share.
- Following these conversions, Inscobee Inc. directly beneficially owns a total of 2,099,747 shares of Apimeds Pharmaceuticals US, Inc. common stock.
- This Form 4/A amends a previous filing from May 14, 2025, to correct an error, clarifying that Inscobee Inc. directly owned the notes and the resulting shares, rather than indirectly through Apimeds Korea.
- The conversions were triggered by the completion of a "Qualified Financing" by Apimeds Pharmaceuticals US, Inc. on May 12, 2025, which resulted in the listing of the Issuer's common stock on a national securities exchange.
Sentiment
Score: 7
Explanation: The conversion of debt to equity strengthens the balance sheet and signifies the successful completion of a 'Qualified Financing' (likely a public listing), which are positive milestones. The correction of the filing also improves transparency. The dilution from conversion is a natural consequence of such financing structures.
Positives
- Conversion of convertible notes reduces the company's debt obligations, strengthening its balance sheet.
- The conversion indicates the successful completion of a "Qualified Financing," which likely involved listing on a national securities exchange, a significant corporate milestone.
- Inscobee Inc., a significant insider (10% owner and director), has increased its direct equity stake in the company, demonstrating continued commitment and confidence.
- The amendment corrects a previous filing, ensuring accuracy and transparency in beneficial ownership reporting.
Negatives
- The conversion of notes into common stock results in dilution for existing shareholders.
Risks
- No new risks are introduced by this specific amendment. The original notes had maturity dates (December 31, 2026), but the conversion occurred earlier due to the Qualified Offering.
Future Outlook
The document indicates that the company completed a "Qualified Financing" on May 12, 2025, which resulted in the listing of its common stock on a national securities exchange. This event triggered the conversion of the outstanding convertible promissory notes, fulfilling a key condition for their maturity.
Management Comments
- On May 14, 2025, the reporting person filed a Form 4, which incorrectly reported that the reporting person had indirect beneficial ownership of the Convertible Promissory Note in the amount of $184,833 (the 'Note') and the shares of common stock underlying such Note (the 'Shares'), through Apimeds Korea. In fact, as reported in this amendment, the reporting person directly owned the Note and the Shares.
Industry Context
This filing details an insider transaction common in the pharmaceutical and biotech sectors, where early-stage companies often rely on convertible debt from strategic investors or insiders. The conversion of these notes upon a "Qualified Financing" (likely an IPO or direct listing) is a standard mechanism for such debt to convert into equity, aligning investor interests with the company's public market debut.
Comparison to Industry Standards
- Not applicable for this type of insider transaction report. This document focuses on a specific company's debt-to-equity conversion and an ownership reporting correction, rather than operational or financial performance metrics that would typically be benchmarked against industry peers.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reporting Correction | Amendment of a previously filed Form 4 to correct the nature of beneficial ownership from indirect (through Apimeds Korea) to direct for Inscobee Inc. regarding convertible promissory notes and underlying shares. | 05/14/2025 (original filing date), 06/11/2025 (amendment filing date) | Enhances transparency and accuracy of insider ownership disclosures, which is a fundamental aspect of corporate governance and regulatory compliance. |
Related Party Transactions
- Issuance and subsequent conversion of two convertible promissory notes (March 2022 Note and June 2022 Note) from Apimeds Pharmaceuticals US, Inc. to Inscobee Inc., which is a 10% owner and director of the Issuer.
Stakeholder Impact
- Shareholders: Experience dilution due to the conversion of convertible notes into common stock, increasing the total number of outstanding shares. However, the conversion also reduces the company's debt burden.
- Creditors (specifically Inscobee Inc. as a former noteholder): Their debt position has been converted into an equity stake, aligning their financial interest more directly with the company's stock performance.
Key Dates
| Date | Description |
|---|---|
| 03/21/2022 | Issuance date of the first convertible promissory note (March 2022 Note) to Inscobee Inc. |
| 06/03/2022 | Issuance date of the second convertible promissory note (June 2022 Note) to Inscobee Inc. |
| 05/12/2025 | Date of earliest transaction; completion of Qualified Financing and conversion of both convertible promissory notes into common stock. |
| 05/14/2025 | Date of original Form 4 filing, which contained an error regarding beneficial ownership. |
| 06/11/2025 | Signature date of the Form 4/A amendment. |
| 12/31/2026 | Maturity date for both convertible promissory notes if a Qualified Offering had not occurred earlier. |
Keywords
SEC Form 4/A, beneficial ownership, insider transaction, convertible promissory note, equity conversion, Apimeds Pharmaceuticals US Inc., APUS, Inscobee Inc., Qualified Financing, debt conversion, stock ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.